Clinical trial
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
NCT00467844 · GTx, Industry · Completed
Key facts
| NCT number | NCT00467844 |
|---|---|
| Title | Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. |
| Official title | Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer |
| Lead sponsor | GTx, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cachexia |
| Intervention type | Drug |
| Interventions | GTx-024, Placebo |
| Enrollment | 159 |
| Start date | May 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 1, 2007 |
| Last update posted | Jul 11, 2014 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: